Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

622 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunophenotyping of Circulating and Intratumoral Myeloid and T Cells in Glioblastoma Patients.
Marx S, Wilken F, Miebach L, Ispirjan M, Kinnen F, Paul S, Bien-Möller S, Freund E, Baldauf J, Fleck S, Siebert N, Lode H, Stahl A, Rauch BH, Singer S, Ritter C, Schroeder HWS, Bekeschus S. Marx S, et al. Among authors: lode h. Cancers (Basel). 2022 Nov 23;14(23):5751. doi: 10.3390/cancers14235751. Cancers (Basel). 2022. PMID: 36497232 Free PMC article.
Validated detection of anti-GD2 antibody ch14.18/CHO in serum of neuroblastoma patients using anti-idiotype antibody ganglidiomab.
Siebert N, Seidel D, Eger C, Brackrock D, Reker D, Schmidt M, Lode HN. Siebert N, et al. J Immunol Methods. 2013 Dec 15;398-399:51-9. doi: 10.1016/j.jim.2013.09.008. Epub 2013 Sep 18. J Immunol Methods. 2013. PMID: 24055592
We recently described the generation and characterization of ganglidiomab, a monoclonal anti-idiotype Ab (AIT) of ch14.18 (Lode et al., 2013), which was used to establish quantitative and validated enzyme-linked immunosorbent assay (ELISA) methods using ganglidiomab as a c …
We recently described the generation and characterization of ganglidiomab, a monoclonal anti-idiotype Ab (AIT) of ch14.18 (Lode et al …
Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival.
Siebert N, Jensen C, Troschke-Meurer S, Zumpe M, Jüttner M, Ehlert K, Kietz S, Müller I, Lode HN. Siebert N, et al. Oncoimmunology. 2016 Sep 26;5(11):e1235108. doi: 10.1080/2162402X.2016.1235108. eCollection 2016. Oncoimmunology. 2016. PMID: 27999754 Free PMC article.
622 results